On June 15, the official website of the National Medical Products Administration (NMPA) showed that luvometinib (FCN-159), independently developed by Fosun Pharmaceutical, has been approved for a new indication: the treatment of pediatric patients aged 2 years and older with Langerhans cell histiocytosis (LCH).
LCH is a clonal hematopoietic neoplasm primarily characterized by activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which can involve various organs and systems throughout the body, with diverse clinical manifestations. Luvometinib is an innovative small-molecule selective MEK1/2 inhibitor independently developed by Fosun Pharma. By blocking the abnormal activation of the MAPK signaling pathway, it inhibits tumor cell proliferation and induces apoptosis.
In a single-arm Phase II study, 25 pediatric patients with relapsed or refractory LCH received luvometinib (5 mg/m² once daily). After a median follow-up of 7.4 months, the objective response rate (ORR) was 84.0% (21/25), including 14 cases of complete metabolic remission (CMR) and 7 cases of partial metabolic remission (PMR). The investigator-assessed ORR was 80.0% (20/25), with 11 CMR and 9 PMR.
Data updated in June of this year showed that after expanding enrollment to 46 patients and extending follow-up to 15.1 months, the ORR reached 90.5%, with 69% of patients achieving CMR. The investigator-assessed ORR reached 97.8%.
Previously, luvometinib was approved for marketing in May 2025 for the treatment of adult patients with LCH and histiocytic neoplasms, as well as pediatric and adolescent patients aged 2 years and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1).
According to the PharmaCube NextPharma database, a total of 7 selective MEK1/2 inhibitors have been approved for marketing globally, including trametinib (Novartis), binimetinib (Pfizer), selumetinib (AstraZeneca), cobimetinib (Roche), tuebatinib (Kezhou Pharmaceutical), mirdametinib (Merck), and luvometinib (Fosun Pharma).